Zenith Drugs Ltd.

NSE: ZENITHDRUG

Zenith Drugs Live Share Price Today, Share Analysis and Chart

Name: Zenith Drugs Ltd.: Is Infosys Ltd. worth buying?
Item: Zenith Drugs Ltd.
Rating: 1.83883325
Author: Trendlyne DVM scores

aboutZenith Drugs Limited is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of a wide range of generic pharmaceutical formulations. The company specializes in producing various dosage forms including tablets, capsule... Read More

-0.10(-0.27%)

42.28% Fall from 52W High

2,400

NSE Volume

NSE 03 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

- / 100

33.7 / 100

No estimates available

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Low rank

3Positive11Negative

21.4%Pass in checklist

045

100

Check P/E Buy Sell Zone

Neutral Zone

40.0 % into P/E buy sell zone

% time spent below current P/E

020406080100

Strong upside potential

Gains already realized

Zenith Drugs Stock Price Analysis

Day Price Range -0.3% 1 Day return	37 (LTP) 3737 LowHigh
Week Price Range -3.9% 1 Week return	37 (LTP) 3738.6 LowHigh
Month Price Range -12.0% 1 Month return	37 (LTP) 36.843.8 LowHigh
52 Week Price Range -43.1% 1 Year return	37 (LTP) 33.364.1 LowHigh

View full Price History/Seasonality

Competitors/Peers

Annual

Balance Sheet

Ratios

Cash Flow

Documents

Zenith Drugs annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Zenith Drugs Mar-2026 Annual Revenue is Rs 176 Cr which is growth of 29.7% YoY.
NEGATIVE
Annual Net Profit Zenith Drugs Mar-2026 Annual Net Profit is Rs 4 Cr which is growth of -44.9% YoY.

Zenith Drugs Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19
SR_A Total Rev. Ann. ⌄	15%	19.1%	176.3	135.9	133.7	115.8	92.6	73.5	78.3	52.2
TotalOperatingRevenues_A Operating Rev. Ann.	14.3%	18.5%	171.2	133.3	131.6	114.5	91.7	73.4	78.3	52.2
OI_A Other Income Ann.	62%	119.5%	5.1	2.6	2.1	1.2	1	0.1	0.1	0
OEXPNS_A Operating Exp. Ann.	14.7%	19.2%	159.1	119.7	114.7	105.5	84.7	66.2	71.2	48.9
OEXPNS_A Operating Exp. Ann.	14.7%	19.2%	159.1	119.7	114.7	105.5	84.7	66.2	71.2	48.9
OP_A Operating Profit Ann.	10.3%	11.1%	12.2	13.6	16.9	9.1	6.9	7.2	7.1	3.3
OPMPCT_A OPM Ann. %	-4.1%	-6.8%	6.90%	9.99%	12.65%	7.82%	7.48%	9.79%	8.99%	6.34%
TotalExpenses_A Total Exp. Ann. ⌄	16.1%	19.9%	170.7	126.4	119	109.1	88.2	68.9	73.5	50.6
OtherExpenses_A Other Exp. Ann.	21.2%	21.6%	27.4	15.1	15.2	15.4	8.4	10.3	10.7	6.1
EmployeeBenefitExpenses_A Employee Exp. Ann.	22.1%	21.1%	9.1	7.3	6.1	5	3.9	3.5	3.9	2.7
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	18.9%	18.8%	17.3	16.2	19	10.3	7.9	7.3	7.1	3.3
EBIDTPCT_A EBITDA Ann. margin %	3.3%	-0.3%	9.79%	11.91%	14.24%	8.89%	8.50%	9.95%	9.07%	6.38%
INT_A Interest Ann.	34.5%	30.1%	5.6	3.7	3	2.3	2.1	1.5	1.3	1
DEP_A Depr.	67.4%	38.4%	6.1	3	1.3	1.3	1.3	1.2	0.9	0.8
PBT_A PBT Ann.	-5.8%	4%	5.6	9.5	14.7	6.7	4.4	4.6	4.9	1.6
TAX_A Tax Ann.	-8%	-1.4%	1.4	2.1	3.8	1.8	1.2	1.5	1.5	0.4
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	-5%	6.3%	4.2	7.4	11	4.9	3.2	3.1	3.4	1.1
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	-7.3%	4.7%	3.9	7.2	9.5	4.9	3.2	3.1	3.4	1.1
NETPCT_A NPM Ann. %	-18.6%	-11.2%	2.30%	5.37%	7.24%	4.26%	3.50%	4.17%	4.34%	2.17%
EPS_adj_A EPS Adj. latest Ann.	-7.4%	5%	2.3	4.2	5.6	2.9	1.9	1.8	2	0.7

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

VIEW ALL TABLE IN FINANCIAL PAGE

Total Rev. Ann.

1Y CHG

29.7%

2Y CAGR

14.8%

3Y CAGR

15%

5Y CAGR

19.1%

7Y CAGR

19%

Total Revenue Annual growth is higher than historical averages.

Net Profit Ann.

1Y CHG

-45.8%

2Y CAGR

-35.9%

3Y CAGR

-7.3%

5Y CAGR

4.7%

7Y CAGR

19.8%

Net Profit Annual is falling faster than historical averages.

Operating Exp. Ann.

1Y CHG

32.9%

2Y CAGR

17.8%

3Y CAGR

14.7%

5Y CAGR

19.2%

7Y CAGR

18.4%

Operating Expenses Annual Cr growth is higher than historical averages.

Zenith Drugs Technical Analysis

Zenith Drugs EMA & SMA

Bearish-8

0 bullish, 8 bearish

Bullish0

Bearish8

5 Day	37.3
10 Day	37.8
12 Day	38.1
20 Day	39.1

26 Day	39.7
50 Day	41.3
100 Day	43.0
200 Day	46.5

Zenith Drugs Delivery And Volume

Daily Avg. Delivery Volume %

03 Nov, 2026100.0%

Week100.0%

Month86.6%

Zenith Drugs Active Candlesticks

Short Line Uptrend

Legend

Positive IndicatorNeutral IndicatorNegative Indicator

Zenith Drugs Resistance and Support

37.00

Pivot

First Resistance	37
Second Resistance	37
Third Resistance	37

First Support	37
Second Support	37
Third Support	37

Day RSI	37.1
Day MACD	-1.6
Day MFI	13.4
Day MACD Signal Line	-1.5

Zenith Drugs Beta

1 Month	0.5
1 Year	-0.2

3 Month	-1.4
3 Year	-

Zenith Drugs Price Change Analysis

↓-12.0%

Over 1 Month

LowHigh

36.843.8

↓-22.6%

Over 3 Months

LowHigh

36.851

↓-7.4%

Over 6 Months

LowHigh

36.854.4

↓-43.1%

Over 1 Year

LowHigh

33.364.1

Zenith Drugs Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026

Name	Category	Shares	Shares %
Ajay Singh Dassundi	Promoter	3,861,990	22.5 %
Clearing Members	Public	93,200	0.5 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Zenith Drugs Deals - Insider, Bulk, Block and SAST

Client Name	Deal Type	Action	Date	Avg. Price	Quantity	Exchange
AMIT GARG	Bulk	Sell	16 Sep 2026	43.10	184,000	NSE
BINDU GARG	Bulk	Purchase	16 Sep 2026	43.10	184,000	NSE
BINDU GARG	Bulk	Sell	10 Aug 2026	41	93,600	NSE
AMIT GARG	Bulk	Purchase	10 Aug 2026	41.07	95,200	NSE
KAVYA GUPTA	Bulk	Sell	07 Jul 2025	74	104,000	NSE
PRIYANKA .	Bulk	Sell	01 Oct 2024	131.81	86,400	NSE
GRETEX SHARE BROKING LIMITED	Bulk	Sell	29 Aug 2024	113.64	88,000	NSE
GRETEX SHARE BROKING LIMITED	Bulk	Purchase	29 Aug 2024	115.30	1,600	NSE
RASHMI RANI PAHWA	Bulk	Purchase	22 Aug 2024	90.35	88,000	NSE
NEOMILE GROWTH FUND - SERIES I	Bulk	Sell	12 Jul 2024	63.15	96,000	NSE

All deals

Zenith Drugs Corporate Actions

Zenith Drugs Dividend history and yield

Zenith Drugs dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Zenith Drugs dividend yield over time.

#Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
117 Sep 2024	0.5	FINAL	18 Sep 2024	Equity Share

Zenith Drugs Board Meetings

Zenith Drugs past and upcoming board meetings.

#Ex-Date	Purpose	Notes
126 Jun 2026	Fund Raising & Others	(Revised) To consider Other business matters.
229 May 2026	Audited Results & Others	To consider Other business matters.
314 Nov 2025	Quarterly Results & Others	To consider Other business matters.
429 May 2025	Audited Results & Others	To consider Other business matters.
517 Apr 2025	To consider Fund Raising & Others	To consider Other business matters. (Revised)

All Corporate Actions

Zenith Drugs DocumentsAsk MarketMind AI

Zenith Drugs Credit Ratings

Zenith Drugs credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

Date	Rating Agency	Company Name	Description	Links
07 Sep 2026	crisil ratings	Zenith Drugs Limited	Zenith Drugs Limited:Ratings migrated to 'Crisil BB+ / Stable / Crisil A4+ '	Link
14 Jun 2026	crisil ratings	Zenith Drugs Limited	Zenith Drugs Limited:Issuer not cooperating, based on best-available information; Ratings continues to be \u2018Crisil BB/Stable/Crisil A4+ Issuer not cooperating\u2019	Link
07 Jun 2026	crisil ratings	Zenith Drugs Limited	Zenith Drugs Limited:Issuer not cooperating, based on best-available information; Ratings migrated to \u2018Crisil BB/Stable/Crisil A4+ Issuer not cooperating\u2019	Link
20 May 2026	crisil ratings	Zenith Drugs Limited	Rating Update : Zenith Drugs Limited	Link
16 Mar 2025	crisil ratings	Zenith Drugs Limited	Zenith Drugs Limited:'Crisil BBB-/Stable/Crisil A3' assigned to Bank Debt	Link

Zenith Drugs - Company Profile

Zenith Drugs Management Structure

Zenith Drugs management structure with salaries, total experience, and qualifications.

NAME	DESIGNATION	GROSS REMUNERATION ₹(LAC)	AS OF	HISTORY & DETAILS
Sakshi Bhawsar	Company Secretary,Compliance Officer	-	Mar 25
Mr. Neeraj Pandey	Chief Financial Officer	-	Mar 25

Zenith Drugs Board of Directors

Zenith Drugs Board of directors with salaries, total experience, and qualifications.

NAME	POSITION	GROSS REMUNERATION ₹(LAC)	AS OF
SANDEEP BHARDWAJ	Executive Director & MD	-	Mar 25
BHUPESH SONI	Executive Director	-	Mar 25
Ajay Singh Dassundi	Executive Director	-	Mar 25
Deendayal Kumawat	Independent Non Exe. Director	-	Mar 25
Anil Malik	Non Executive Director	-	Mar 25
RANJANA SEHGAL	Independent Non Exe. Director	-	Mar 25
Sakshi Bhawsar	Company Sec. & Compli. Officer	-	Mar 25

About

Website: www.zenithdrugs.com

About the company - Business Profile

Zenith Drugs Limited is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of a wide range of generic pharmaceutical formulations. The company specializes in producing various dosage forms including tablets, capsules, and liquid orals across multiple therapeutic segments. It operates as a formulation manufacturer catering to both domestic and international markets, focusing on providing affordable healthcare solutions through generic medicines.

Key Points

Key Facts: Zenith Drugs Limited was incorporated in 2000 and is headquartered in Indore, Madhya Pradesh. The company is listed on the NSE SME platform. Its core business involves the development and manufacturing of high-quality pharmaceutical products.
Operations and Resources: The company operates a manufacturing facility located in Indore, which is designed to meet regulatory standards for pharmaceutical production. This facility is equipped for the large-scale manufacture of diverse dosage forms.
Ownership: Zenith Drugs is a publicly traded company on the NSE SME exchange following its initial public offering. The management team is led by Sandeep Bhardwaj, serving as the Managing Director.
Market and Significance: The company serves various therapeutic areas including antibiotics, anti-inflammatory drugs, anti-diabetics, and cardiovascular treatments. It holds a significant position in the SME segment of the Indian pharmaceutical industry, with a focus on expanding its footprint in emerging markets through exports.
Business Model: The company operates a manufacturing-led business model. It is proficient in formulation development and bulk production of generic drugs. It leverages its cost-effective manufacturing capabilities to compete in both the contract manufacturing (CMO) space and the branded generic market.
Revenue Breakdown: For the financial year ended March 31, 2025, the company reported a total revenue from operations of ₹1,116.12 lakh. This is a decrease from the previous year’s revenue of ₹1,447.17 lakh (FY 2024).
- Domestic Sales: ₹222.46 lakh (FY 2025).
- Export Sales: ₹893.66 lakh (FY 2025).
- The export segment remains a major contributor to the company’s total turnover, highlighting its international market focus.
Key Products and Advancements: Zenith Drugs manufactures a diverse portfolio including:
- Antibiotics: Broad-spectrum antibacterial formulations.
- Gastrointestinal: Medicines for digestive health and acidity.
- Nutraceuticals: Vitamin and mineral supplements.
- The company focuses on maintaining a robust product pipeline to cater to chronic and acute therapeutic segments.
Subsidiaries: The company does not report any major active subsidiaries in its latest financial filings, focusing its operations through the parent entity.
Strategic Initiatives: Current efforts are centered on expanding its export portfolio and securing regulatory approvals in additional international territories. The company is also focused on optimizing its manufacturing processes to improve margins and enhance production efficiency.

Zenith Drugs FAQ

Zenith Drugs today is trading in the red, down by 0.27% at ₹37.

Zenith Drugs is currently trading down 0.27% on an intraday basis. In the past week the stock fell 3.9%. Stock has been down 22.59% in the past quarter and fell 43.12% in the past year. You can view this in the share price history/seasonality section.

Zenith Drugs is listed on NSE with the ticker ZENITHDRUG. It's currently trading on NSE at a share price of ₹37.

The market cap of Zenith Drugs is ₹63.45 Cr. as of Nov 03, 2026.

Zenith Drugs announced a FINAL dividend of 5% which equals ₹0.5 in Sep 17, 2024.To view the full dividend history of Zenith Drugs click here.

Zenith Drugs has never issued stock splits or bonus shares since the time of its listing on the NSE exchange.

Zenith Drugs reported ₹176.32 Cr. in revenue, ₹3.94 Cr. in net profit, and ₹17.26 Cr. in EBITD as of Mar 31, 2026 for FY25-26.

There are no analyst predictions for stock price target for Zenith Drugs.

The PE ratio of Zenith Drugs is 16.09 as of Nov 03, 2026.

The PB ratio of Zenith Drugs is 0.85 as of Nov 03, 2026.

There are no analyst reports for Zenith Drugs.

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

Zenith Drugs Live Share Price Today, Share Analysis and Chart

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Zenith Drugs Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Zenith Drugs - Annual

Zenith Drugs annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Annual Revenue Zenith Drugs Mar-2026 Annual Revenue is Rs 176 Cr which is growth of 29.7% YoY.

Annual Net Profit Zenith Drugs Mar-2026 Annual Net Profit is Rs 4 Cr which is growth of -44.9% YoY.

Zenith Drugs Technical Analysis

Zenith Drugs EMA & SMA

Zenith Drugs Delivery And Volume

Zenith Drugs Active Candlesticks

Zenith Drugs Resistance and Support

Zenith Drugs Beta

Zenith Drugs Price Change Analysis

Zenith Drugs Shareholding Pattern/ Ownership

Shareholding Summary

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Zenith Drugs Deals - Insider, Bulk, Block and SAST

Bulk Block Deals

Zenith Drugs Corporate Actions

Zenith Drugs Dividend history and yield

Zenith Drugs dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Zenith Drugs dividend yield over time.

Zenith Drugs Board Meetings

Zenith Drugs past and upcoming board meetings.

Zenith Drugs DocumentsAsk MarketMind AI

Zenith Drugs Credit Ratings

Zenith Drugs credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

Zenith Drugs - Company Profile

Zenith Drugs Management Structure

Zenith Drugs management structure with salaries, total experience, and qualifications.

Zenith Drugs Board of Directors

Zenith Drugs Board of directors with salaries, total experience, and qualifications.

About the company - Business Profile

Key Points

Zenith Drugs FAQ

How is Zenith Drugs today?

Zenith Drugs today is trading in the red, down by 0.27% at ₹37.

How has Zenith Drugs performed historically?

Zenith Drugs is currently trading down 0.27% on an intraday basis. In the past week the stock fell 3.9%. Stock has been down 22.59% in the past quarter and fell 43.12% in the past year. You can view this in the share price history/seasonality section.

What is the current share price of Zenith Drugs on NSE and BSE exchanges?

Zenith Drugs is listed on NSE with the ticker ZENITHDRUG. It's currently trading on NSE at a share price of ₹37.

What is the market cap of Zenith Drugs?

The market cap of Zenith Drugs is ₹63.45 Cr. as of Nov 03, 2026.

When did Zenith Drugs last pay a dividend, and what has its dividend history been?

Zenith Drugs announced a FINAL dividend of 5% which equals ₹0.5 in Sep 17, 2024.To view the full dividend history of Zenith Drugs click here.

Has Zenith Drugs issued any bonus shares or share splits recently?

Zenith Drugs has never issued stock splits or bonus shares since the time of its listing on the NSE exchange.

What do the financial statements and annual reports of Zenith Drugs Indicate?

Zenith Drugs reported ₹176.32 Cr. in revenue, ₹3.94 Cr. in net profit, and ₹17.26 Cr. in EBITD as of Mar 31, 2026 for FY25-26.

What is the target share price of Zenith Drugs according to analyst predictions in FY26-27?

There are no analyst predictions for stock price target for Zenith Drugs.

What is the PE Ratio of Zenith Drugs?

The PE ratio of Zenith Drugs is 16.09 as of Nov 03, 2026.

What is the PB Ratio of Zenith Drugs?

The PB ratio of Zenith Drugs is 0.85 as of Nov 03, 2026.

Where can I check the latest Research Reports about Zenith Drugs?

There are no analyst reports for Zenith Drugs.

How can I be notified of real time alerts about Zenith Drugs stock?

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.